Clinical Trial News and Research

RSS

CNS Pharmaceuticals' common shares sponsored by 886 AG on the electronic trading platform Xetra

CNS PHARMACEUTICALS AG, (C35.F) a developer and marketer of patented natural nutraceutical products is pleased to announce that the Company’s common shares is sponsored by the German Securities Trading Bank 886 AG Wertpapier Handelsbank on the electronic trading platform Xetra.

13 Nov 2009

Pharmacyclics to present clinical updates and posters relating to PCI-24781 and PCI-32765

Pharmacyclics, Inc. today announced that posters related to PCI-24781 and PCI-32765 have been selected for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH), December 5-8, 2009 in New Orleans, LA.

13 Nov 2009

Axelar AB to present data from ongoing Phase I/II clinical trial of AXL1717

Axelar AB today announced that promising data from the ongoing Phase I/II clinical trial concerning their lead anticancer product AXL1717, an insulin-like growth factor-1 (IGF-1) receptor inhibitor, will be presented next week at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, Massachusetts, USA.

13 Nov 2009

Abbott signs agreement to acquire global rights to PanGenetics BV's PG110

Abbott announced today a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company's pain care portfolio and leveraging its expertise in biologics. PG110 is a novel biologic in Phase I clinical trial development that targets NGF for the treatment of chronic pain.

13 Nov 2009

Cancer patients with dense breasts have a higher risk of recurring malignancy

A study published in the current issue of Cancer found that breast cancer patients with dense breasts have a 4x higher risk of recurring malignancy.

13 Nov 2009

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

PanGenetics, an antibody development company which is developing PG110, a humanized antibody to Nerve Growth Factor (NGF), today announced it has entered into an agreement with Abbott under which Abbott will acquire the global rights to this novel biologic. PG110 is currently in a Phase 1 clinical trial in patients with osteoarthritis and represents a promising new therapeutic for the treatment of chronic pain.

13 Nov 2009

Positive results from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS

Lexicon Pharmaceuticals, Inc. announced today that the company's investigational new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated positive results in clinically important parameters for the treatment of non-constipating irritable bowel syndrome (IBS).

13 Nov 2009

ARYx Therapeutics announces operating results for the third quarter of 2009

ARYx Therapeutics, Inc. today reported results of operations and provided a general business update for the third quarter ended September 30, 2009.

12 Nov 2009

Cequent Pharmaceuticals proposes the first test of an orally administered RNA interference drug in humans

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has announced that it has filed its first IND (investigational new drug) application with the U.S. Food and Drug Administration (FDA).

12 Nov 2009

Pharmos announces financial results for the third quarter of 2009

Pharmos Corporation today reported financial results for the third quarter and nine-month period ended September 30, 2009.

12 Nov 2009

Third-quarter 2009 results announced by Neurologix

Neurologix, Inc., a biotechnology company engaged in the development of innovative gene therapies for the brain and central nervous system, announced today its financial results for the third quarter and nine months ended September 30, 2009.

12 Nov 2009

American Medical Alert announces operating results for the third quarter of 2009

American Medical Alert Corp. a provider of healthcare communication services and advanced telehealth monitoring technologies, today announced operating results for the quarter and nine months ended September 30, 2009.

12 Nov 2009

Update on Alnylam Pharmaceuticals' RNAi pipeline, platform, and technology

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, is providing an update on its RNAi pipeline, platform, and technology at its R&D Day being held in New York today.

12 Nov 2009

Financial results for third-quarter 2009 announced by Spectral Diagnostics

Spectral Diagnostics Inc., today announced its financial results for the third quarter ended September 30, 2009.

12 Nov 2009

Bradmer Pharmaceuticals reports financial results for the third quarter of 2009

Bradmer Pharmaceuticals Inc. today announced its 2009 third quarter financial results.

12 Nov 2009

Keryx Biopharmaceuticals to present KRX-0401 Phase 1/2 clinical trial data at the ASH meeting

Keryx Biopharmaceuticals, Inc. today announced that data from its Phase 1/2 clinical trial of KRX-0401 (perifosine) in combination with bortezomib (+/- dexamethasone) has been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009.

12 Nov 2009

Trubion Pharmaceuticals to present data on its TRU-016 product candidate at the ASH meeting

Trubion Pharmaceuticals, Inc. announced today the acceptance of two data presentations on its product candidate, TRU-016, at the 2009 American Society of Hematology (ASH) Annual Meeting Dec. 5-8, 2009 in New Orleans, Louisiana.

12 Nov 2009

Gene therapy increases muscle size and strength with no adverse effects in monkeys: MDA

Four macaque monkeys that received injections of genes for a protein called follistatin into upper leg muscles experienced pronounced and durable increases in muscle size and strength and no adverse effects, the Muscular Dystrophy Association (MDA) announced today. The findings could have implications particularly for injured and aging people worldwide; and for tens of millions experiencing muscle loss associated with cancer, AIDs and muscle diseases.

12 Nov 2009

Canadian researchers organize clinical trials to find new treatments for H1N1 infection

An important, ground-breaking initiative is unfolding in the global critical care community in response to the H1N1 pandemic.

12 Nov 2009

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it is developing ADCC TherasightTM, a novel theragnostic product that can help guide the drug development process and patient treatment protocols for the cancer therapeutic antibodies that use ADCC (antibody-dependent cellular cytotoxicity) as the major mechanism of action.

12 Nov 2009

Clinical Trial News and Research

CNS Pharmaceuticals' common shares sponsored by 886 AG on the electronic trading platform Xetra

Pharmacyclics to present clinical updates and posters relating to PCI-24781 and PCI-32765

Axelar AB to present data from ongoing Phase I/II clinical trial of AXL1717

Abbott signs agreement to acquire global rights to PanGenetics BV's PG110

Cancer patients with dense breasts have a higher risk of recurring malignancy

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

Positive results from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS

ARYx Therapeutics announces operating results for the third quarter of 2009

Cequent Pharmaceuticals proposes the first test of an orally administered RNA interference drug in humans

Pharmos announces financial results for the third quarter of 2009

Third-quarter 2009 results announced by Neurologix

American Medical Alert announces operating results for the third quarter of 2009

Update on Alnylam Pharmaceuticals' RNAi pipeline, platform, and technology

Financial results for third-quarter 2009 announced by Spectral Diagnostics

Bradmer Pharmaceuticals reports financial results for the third quarter of 2009

Keryx Biopharmaceuticals to present KRX-0401 Phase 1/2 clinical trial data at the ASH meeting

Trubion Pharmaceuticals to present data on its TRU-016 product candidate at the ASH meeting

Gene therapy increases muscle size and strength with no adverse effects in monkeys: MDA

Canadian researchers organize clinical trials to find new treatments for H1N1 infection

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery